Updated:
HYPERION THERAPEUTICS INC
HYPERION THERAPEUTICS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001386858, and its reported...
Overview
HYPERION THERAPEUTICS INC is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001386858, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2015-03-04, it reported annual revenue of USD 113,584,000; net income of USD -6,255,000; total assets of USD 180,416,000 for the fiscal period ended 2014-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- HYPERION THERAPEUTICS INC
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Brisbane, CA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001386858
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2014USD | $113.6M | -$6.3M | $180.4M | $102.8M | — | |
| FY2013USD | — | $16.6M | $142.5M | $74.2M | -$1.2M | |
| FY2012USD | — | -$32.3M | $51.2M | $49.9M | -$28.5M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 10-Q | FORM 10-Q | ||
| 10-K/A | 10-K/A | ||
| SC 13D | — | Form SC 13D | |
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 10-K | FORM 10-K | ||
| 8-K | FORM 8-K FILING DOCUMENT | ||
| 8-K | FORM 8-K | ||
| SC 13G | — | CONSONANCE CAPITAL MANAGEMENT LP | |
| 8-K | FORM 8-K | ||
| 10-Q | 10-Q |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research HYPERION THERAPEUTICS INC in Altss
Track this company’s investors, transactions and relationships in Altss.